SCHEMBL3816401

SCHEMBL3816401

Cc1ccncc1-c1nc(-c2ccc(S(N)(=O)=O)cc2)cs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.51
KDM4E B2RXH2 4/20 0.50
SMN1; SMN2 Q16637 5/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 1/20 0.48
PTGS2 P35354 2/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
ALDH1A1 P00352 4/20 0.45
USP2 O75604 2/20 0.45
HPGD P15428 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HSD17B10 Q99714 2/20 0.45
GAA P10253 2/20 0.45
GFER P55789 1/20 0.45
LRRK2 Q5S007 1/20 0.45
MAPT P10636 4/20 0.44
MAPK1 P28482 2/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3820634 0.91 CYP19A1 (0.50) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3821580 0.84 KDM4E (0.61) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3821159 0.82 KDM4E (0.45) CYP19A1KDM4ESMN1; SMN2NPC1PTGS2
SCHEMBL3813419 0.80 KDM4E (0.66) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL6648628 0.80 CYP19A1 (0.60) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3814593 0.80 KDM4E (0.66) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3821571 0.80 PIM1 (0.54) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3821585 0.80 CYP19A1 (0.46) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3823800 0.79 RAB9A (0.59) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3818666 0.78 CYP19A1 (0.55) CYP19A1KDM4ESMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1348706-B1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-08-19 EP claimed
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-15 US claimed
EP-1348706-A1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-01 EP claimed
EP-1348706-B1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-08-19 EP disclosed
US-7067537-B2 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-15 US disclosed
EP-1348706-A1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof CYP17A1, CYP21A2, HSD17B1 CYP19A1 10/4885KDM4E 1126/4885SMN1; SMN2 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.